Status:
COMPLETED
Exploring Brain Damages After COVID-19 Infection
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
SARS-CoV 2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Although direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the Central Nervous System (CNS). Indeed, so...
Detailed Description
Clinical and preclinical data from studies with other coronaviruses suggest an evident neurotropism, which may result in more complex clinical scenarios. Can the SARS-CoV-2 enter the Central Nervous S...
Eligibility Criteria
Inclusion
- Inclusion Criteria :
- Age ≥ 18 years.
- Hospitalized patient suffering from a positive COVID 19 diagnosed by Reverse transcription polymerase chain reaction (RT-PCR) or chest computed tomography scan (CTscan) with specific lesions
- Exclusion Criteria :
- History of neurological damage interfering with auditory evoked potentials (PEA) and Electromyography (EMG) reflexes of the brainstem (stroke of the brainstem, acoustic neuroma, amyotrophic lateral sclerosis, facial diplegia, damage to nerves V or VII, etc.)
- Impaired alertness
- Sedative treatments or treatments that disturb nerve conduction.
- Pregnancy or breastfeeding
- Individuals under legal protection or unable to express personally their consent
Exclusion
Key Trial Info
Start Date :
May 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 10 2021
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04405986
Start Date
May 19 2020
End Date
March 10 2021
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France, 33 076